| Description | PBD-150 is an inhibitor of human glutaminyl cyclase (hQC) Y115E-Y117E variant( ki : 490 nM) |
| In vivo | A glutaminyl cyclase (QC) inhibitor, PBD150, was shown to be able to reduce the deposition of pyroglutamate-modified amyloid-β peptides in brain of transgenic mouse models of Alzheimer disease, leading to a significant improvement of learning and memory in those transgenic animals[1]. |
| molecular weight | 320.41 |
| Molecular formula | C15H20N4O2S |
| CAS | 790663-33-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 125 mg/mL (390.13 mM), Sonication is recommended. |
| References | 1. Huang, K.-F, Liaw, S.-S, Huang, W.-L,et al. Structures of Human Golgi-resident Glutaminyl Cyclase and Its Complexes with Inhibitors Reveal a Large Loop Movement upon Inhibitor Binding[J]. Journal of Biological Chemistry, 286(14):12439-12449. 2. Dipisa F , Pozzi C , Benvenuti M , et al. The soluble Y115E–Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease[J]. Acta Crystallographica, 2015, 71(8):986-992. |